Biologics for Crohn's Go Head to Head

Ustekinumab, adalimumab both effective in SEAVUE trial, with no difference in remissions

Related Keywords

New York ,United States ,Temple University ,Pennsylvania ,Chicago ,Illinois ,Allegheny Center ,Philadelphia ,Pbruce Sands ,Adam Ehrlich ,Jack Satsangi ,Zaina Hamza ,Thomas Chapman ,Pustekinumab Stelara ,Sandra El Hachem ,Icahn School Of Medicine At Mount Sinai ,University Of Oxford ,Digestive Health In Pittsburgh ,Disease Activity Index ,Icahn School ,Mount Sinai ,New York City ,Digestive Health ,Medpage Today ,